Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$16.36 - $21.78 $16,899 - $22,498
1,033 Added 115.81%
1,925 $32,000
Q1 2024

May 14, 2024

BUY
$12.08 - $18.56 $10,775 - $16,555
892 New
892 $14,000
Q4 2022

Feb 14, 2023

BUY
$7.65 - $15.51 $646,616 - $1.31 Million
84,525 New
84,525 $1.25 Million
Q2 2022

Aug 15, 2022

SELL
$8.59 - $20.77 $257,820 - $623,390
-30,014 Reduced 46.45%
34,598 $437,000
Q1 2022

May 09, 2022

BUY
$15.52 - $35.65 $1 Million - $2.3 Million
64,612 New
64,612 $1.22 Million
Q2 2021

Aug 13, 2021

SELL
$23.7 - $39.27 $317,627 - $526,296
-13,402 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$27.01 - $36.8 $361,988 - $493,193
13,402 New
13,402 $379,000
Q4 2019

Feb 13, 2020

SELL
$17.17 - $25.95 $333,012 - $503,300
-19,395 Closed
0 $0
Q3 2019

Nov 13, 2019

SELL
$17.84 - $22.69 $10,793 - $13,727
-605 Reduced 3.03%
19,395 $346,000
Q2 2019

Aug 02, 2019

BUY
$22.0 - $31.78 $440,000 - $635,600
20,000 New
20,000 $440,000

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $2.47B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.